3. Why buy CRISPR Therapeutics and not the others? – Motley Fool
San Times |
3. Why buy CRISPR Therapeutics and not the others?
Motley Fool So why does Piper Jaffray prefer CRISPR Therapeutics over its gene-editing rivals? As explained in a note on StreetInsider.com (requires subscription) today, the day is rapidly approaching in which someone will conduct a "First-in-man" trial of CRISPR … Piper Jaffray Assumes CRISPR Therapeutics (CRSP) at Overweight Crispr Therapeutics (NASDAQ:CRSP) Earns Daily Media Sentiment Score of 0.08 Crispr Therapeutics (CRSP) Research Coverage Started at Piper Jaffray Companies |
